用于瘤内免疫调节的新城疫病毒的设计与生产。
Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
作者信息
Vijayakumar Gayathri, Zamarin Dmitriy
机构信息
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
Abstract
Newcastle disease virus (NDV) is an avian paramyxovirus that has been extensively studied as an oncolytic agent, in addition to being an economically important pathogen in the poultry industry. The establishment of a reverse genetics system for this virus has enabled the development of genetically modified recombinant NDV viruses with improved oncolytic and immunotherapeutic properties. In this chapter, we describe the materials and methods involved in the in vitro cloning and rescue of NDV expressing murine 4-1BBL as well as the in vivo evaluation of NDV expressing 4-1BBL in a B16-F10 murine melanoma model.
摘要
新城疫病毒（NDV）是一种禽副粘病毒，除了是家禽业中具有重要经济意义的病原体之外，还作为一种溶瘤剂受到了广泛研究。该病毒反向遗传学系统的建立，使得具有改进的溶瘤和免疫治疗特性的基因工程重组NDV病毒得以开发。在本章中，我们描述了表达小鼠4-1BBL的NDV体外克隆和拯救所涉及的材料和方法，以及在B16-F10小鼠黑色素瘤模型中对表达4-1BBL的NDV进行体内评估的情况。
相似文献
1
Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
2
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
J Virol. 2016 May 12;90(11):5343-5352. doi: 10.1128/JVI.00136-16. Print 2016 Jun 1.
3
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31.
4
Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Discov Med. 2020 Jul-Aug;30(159):39-48.
5
The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy.
Viruses. 2024 May 30;16(6):886. doi: 10.3390/v16060886.
6
Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
Virus Res. 2017 Apr 2;233:35-41. doi: 10.1016/j.virusres.2017.03.003. Epub 2017 Mar 7.
7
Newcastle disease virus: a promising agent for tumour immunotherapy.
Clin Exp Pharmacol Physiol. 2012 Aug;39(8):725-30. doi: 10.1111/j.1440-1681.2011.05662.x.
8
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01677-19.
9
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Methods Mol Biol. 2012;797:177-204. doi: 10.1007/978-1-61779-340-0_13.
10
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Expert Opin Biol Ther. 2015;15(12):1757-71. doi: 10.1517/14712598.2015.1088000. Epub 2015 Oct 5.
引用本文的文献
1
Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma-a promising innovative approach.
Front Oncol. 2025 Aug 7;15:1631155. doi: 10.3389/fonc.2025.1631155. eCollection 2025.
2
PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production.
bioRxiv. 2025 Jun 24:2025.06.23.661172. doi: 10.1101/2025.06.23.661172.
3
Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.
Viruses. 2022 May 6;14(5):975. doi: 10.3390/v14050975.
4
Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.
Vaccines (Basel). 2021 Nov 16;9(11):1335. doi: 10.3390/vaccines9111335.
5
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
Nat Commun. 2021 Oct 27;12(1):6197. doi: 10.1038/s41467-021-26499-y.
6
Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.
Animals (Basel). 2021 Jul 8;11(7):2039. doi: 10.3390/ani11072039.
7
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.
Vaccines (Basel). 2020 Dec 17;8(4):771. doi: 10.3390/vaccines8040771.
8
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
EBioMedicine. 2020 Dec;62:103132. doi: 10.1016/j.ebiom.2020.103132. Epub 2020 Nov 21.
9
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01677-19.
10
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.
本文引用的文献
1
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614.
2
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
Biomedicines. 2016 Jul 20;4(3):16. doi: 10.3390/biomedicines4030016.
3
Efficient and Robust Reverse Genetics Systems.
mSphere. 2017 Mar 29;2(2). doi: 10.1128/mSphere.00376-16. eCollection 2017 Mar-Apr.
4
Rescue of recombinant Newcastle disease virus: a short history of how it all started.
Arch Virol. 2017 Jul;162(7):1845-1854. doi: 10.1007/s00705-017-3308-2. Epub 2017 Mar 18.
5
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340.
6
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
Viruses. 2016 Jul 4;8(7):183. doi: 10.3390/v8070183.
7
P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression.
J Gen Virol. 2015 Jan;96(Pt 1):40-45. doi: 10.1099/vir.0.068437-0. Epub 2014 Oct 1.
8
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.
9
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Future Microbiol. 2012 Mar;7(3):347-67. doi: 10.2217/fmb.12.4.
10
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.
Head Neck. 2011 Oct;33(10):1394-9. doi: 10.1002/hed.21609. Epub 2010 Nov 4.
Zotero 插件